My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Exelixis, Inc. - Common Stock (NQ:EXEL)

41.69 +0.95 (+2.33%)

Official Closing Price Updated: 4:15 PM EST, Mar 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Global Markets Rally on Hopes for US Government Shutdown Resolution

November 10, 2025

Global financial markets are breathing a collective sigh of relief, with stock futures surging as investors cling to cautious optimism for an imminent end to the protracted United States government...

Via MarketMinute

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Preview: Exelixis's Earnings ↗

November 03, 2025

Via Benzinga

17 Analysts Have This To Say About Exelixis ↗

September 17, 2025

Via Benzinga

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

November 06, 2025

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

November 04, 2025

From Exelixis, Inc.

Via Business Wire

What's Driving the Market Sentiment Around Exelixis Inc? ↗

October 30, 2025

Via Benzinga

Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer ↗

October 28, 2025

Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in advanced kidney cancer.

Via Benzinga

Peering Into Exelixis's Recent Short Interest ↗

September 15, 2025

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL) Represents an Affordable Growth Opportunity ↗

October 28, 2025

Discover EXELIXIS (EXEL), an affordable growth stock with strong profitability, sound finances, and a compelling valuation in the biotech sector.

Via Chartmill

Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

October 21, 2025

From Exelixis, Inc.

Via Business Wire

This Nextracker Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

October 21, 2025

Via Benzinga

Top 3 Health Care Stocks You'll Regret Missing In October ↗

October 21, 2025

Via Benzinga

Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results ↗

October 20, 2025

Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer patients.

Via Benzinga

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

October 20, 2025

Via Benzinga

Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗

October 20, 2025

Via Benzinga

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025

October 18, 2025

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet

October 20, 2025

From Exelixis, Inc.

Via Business Wire

The Ultimate Biotech Stock to Buy With $50 Right Now ↗

October 14, 2025

This innovative drugmaker still has plenty of upside potential.

Via The Motley Fool

EXELIXIS INC (NASDAQ:EXEL) Identified as a Quality Value Stock by Fundamental Screening ↗

October 07, 2025

Exelixis (EXEL) presents a strong value investment case with low P/E ratios, zero debt, robust profitability, and solid growth in the biotech sector.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) Stands Out as an Affordable Growth Stock ↗

October 04, 2025

Discover EXELIXIS INC (EXEL), an affordable growth stock with strong financials, impressive earnings, and a discounted valuation in the biotech sector.

Via Chartmill

Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years ↗

September 30, 2025

Both should have significant catalysts by the end of the decade.

Via The Motley Fool

EXELIXIS INC (NASDAQ:EXEL) Emerges as a Top Undervalued Stock with Strong Fundamentals ↗

September 15, 2025

EXELIXIS (EXEL) emerges as a top value stock with strong fundamentals: undervalued, zero debt, high profitability, and solid growth in the biotech sector.

Via Chartmill

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

September 14, 2025

From Pomerantz LLP

Via GlobeNewswire

Exelixis Inc (NASDAQ:EXEL) Embodies the Affordable Growth Investment Strategy ↗

September 13, 2025

Exelixis (EXEL) offers affordable growth with strong oncology revenue, high profitability, a robust balance sheet, and attractive valuation metrics.

Via Chartmill

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

September 10, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

September 06, 2025

From Pomerantz LLP

Via GlobeNewswire

EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm

September 02, 2025

From The Schall Law Firm

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

September 02, 2025

From Pomerantz LLP

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.